VIA
PCRX icon

Virtus Investment Advisers’s Pacira BioSciences PCRX Stock Holding History

Virtus Investment Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,500
Closed -$122K – 636
2024
Q4 		$122K Hold
6,500
– – 0.1% 241
2024
Q3 		$97.8K Buy
+6,500
New +$111K 0.08% 252

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Virtus Investment Advisers's PCRX Position: Q1 2025 in Review

Virtus Investment Advisers sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 6,500 shares — an estimated $122K sold.

Virtus Investment Advisers first reported a position in PCRX in Q3 2024 and held it in 2 quarters. The position peaked at $122K in Q4 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Virtus Investment Advisers reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 6,500 Pacira BioSciences shares in Q1 2025, an estimated $122K.
  • Virtus Investment Advisers first reported a position in Pacira BioSciences in Q3 2024 and held it in 2 quarters.
  • Virtus Investment Advisers's Pacira BioSciences position peaked at $122K in Q4 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Virtus Investment Advisers's 13F filing for Q1 2025, filed 15 May 2025.